|
1
|
Liao W, Liang H, Liang Y, Gao X, Liao G, Cai S, Liu L, Chen S. Factors Associated with IgG/IgM Levels after SARS-CoV-2 Vaccination in Patients with Head and Neck Cancer. Trop Med Infect Dis 2024; 9:234. [PMID: 39453261 PMCID: PMC11511189 DOI: 10.3390/tropicalmed9100234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2024] [Revised: 09/16/2024] [Accepted: 09/26/2024] [Indexed: 10/26/2024] Open
Abstract
This study evaluated the factors influencing IgG/IgM antibody levels in 120 patients with head and neck cancer (HNC) following vaccination with inactivated SARS-CoV-2 vaccines. Each patient's demographic and clinical data were documented, and serum IgG and IgM antibodies were detected using a commercial magnetic chemiluminescence enzyme immunoassay kit. The results indicated that while all patients had received at least one vaccine dose, 95 tested positive for IgG and 25 were negative. A higher proportion of IgG-positive patients had received three vaccine doses. Comparatively, gamma-glutamyl transferase levels were elevated in IgM-negative patients. The study further differentiated patients based on their treatment status: 46 were treatment-naive and 74 had received chemotherapy combined with immune checkpoint inhibitors (ICT) at enrollment. Despite similar baseline characteristics and time from vaccination to antibody detection, IgM positivity was significantly lower in the ICT group, with no significant difference in IgG positivity between the treatment-naive and ICT groups. A multivariable analysis identified the number of vaccine doses as an independent factor of IgG positivity, while ICT emerged as an independent risk factor for IgM positivity. Additionally, IgG titers generally declined over time, although patients with higher baseline IgG levels maintained higher titers longer. In conclusion, ICT in patients with HNC does not significantly affect IgG levels post-vaccination. However, booster vaccinations have been shown to be associated with higher IgG positivity, although these levels gradually decrease over time.
Collapse
Affiliation(s)
- Wei Liao
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China; (W.L.); (H.L.); (X.G.); (L.L.)
- Department of Intensive Care Unit, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - Haoyu Liang
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China; (W.L.); (H.L.); (X.G.); (L.L.)
- Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - Yujian Liang
- Department of Pediatrics, Sun Yat-sen University First Affiliated Hospital, Guangzhou 510060, China;
| | - Xianlu Gao
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China; (W.L.); (H.L.); (X.G.); (L.L.)
- Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - Guichan Liao
- Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China;
| | - Shaohang Cai
- Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China;
| | - Lili Liu
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China; (W.L.); (H.L.); (X.G.); (L.L.)
- Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - Shuwei Chen
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China; (W.L.); (H.L.); (X.G.); (L.L.)
- Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| |
Collapse
|
|
2
|
Aguilar JC, Akbar SMF, Al-Mahtab M, Khan MSI, Guzman CA, Fernandez G, Aguiar JA, Michel ML, Bourgine M, Marrero MA, Trittel S, Ebensen T, Riese P, Le Grand R, Herate C, Mauras A, Yoshida O, Hiasa Y, Penton E, Guillen GE. HeberNasvac: Development and Application in the Context of Chronic Hepatitis B. Euroasian J Hepatogastroenterol 2024; 14:221-237. [PMID: 39802853 PMCID: PMC11714097 DOI: 10.5005/jp-journals-10018-1457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/28/2024] [Accepted: 11/28/2024] [Indexed: 01/16/2025] Open
Abstract
The immune system plays a central role in controlling acute hepatitis B infection and in patients resolving chronic hepatitis B (CHB). Given that 221 million (75%) of CHB patients reside in low- and middle-income countries, the development of a vaccine with therapeutic properties represents a rational and cost-effective approach more than a romantic endeavor. This review systematically analyzes the key variables related to the safety, efficacy, and effectiveness of CHB treatments. HeberNasvac experience is revisited for addressing the challenges and potentialities of therapeutic vaccines, as well as the current roadblocks in research and development, registration, and large-scale implementation. How to cite this article Aguilar JC, Akbar SMF, Al-Mahtab M, et al. HeberNasvac: Development and Application in the Context of Chronic Hepatitis B. Euroasian J Hepato-Gastroenterol 2024;14(2):221-237.
Collapse
Affiliation(s)
- Julio C Aguilar
- Department of Vaccines, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| | - Sheikh MF Akbar
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon City, Japan
| | - Mamun Al-Mahtab
- Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
| | - Md Sakirul I Khan
- Department of Research Center for Global and Local Infectious Diseases, Oita University, Oita, Japan
| | - Carlos A Guzman
- Department of Vaccinology and Applied Microbiology, Helmholtz Center for Infection Research (HZI), Braunschweig, Germany
| | - Guillermo Fernandez
- Department of Gastroenterology, Abel Santamaría Hospital, Pinar del Rio, Cuba
| | - Jorge A Aguiar
- Department of Vaccines, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| | - Marie-Louise Michel
- Laboratory of Hepatitis B Virus Pathogenesis, Institut Pasteur, Paris, France
| | - Maryline Bourgine
- Department of Institut Pasteur-TheraVectys Joint Lab, Institut Pasteur Paris, France
| | - Maria A Marrero
- Department of Clinical Trials, National Coordinating Center for Clinical Trials (CENCEC), Havana, Cuba
| | - Stephanie Trittel
- Department of Vaccinology and Applied Microbiology, Helmholtz Center for Infection Research (HZI), Braunschweig, Germany
| | - Thomas Ebensen
- Department of Vaccinology and Applied Microbiology, Helmholtz Center for Infection Research (HZI), Braunschweig, Germany
| | - Peggy Riese
- Department of Vaccinology and Applied Microbiology, Helmholtz Center for Infection Research (HZI), Braunschweig, Germany
| | - Roger Le Grand
- Department of Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Paris, France
| | - Cecile Herate
- Department of Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Paris, France
| | - Aurelie Mauras
- Department of Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Paris, France
| | - Osamu Yoshida
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon City, Japan
| | - Yoichi Hiasa
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon City, Japan
| | - Eduardo Penton
- Department of Vaccines, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| | - Gerardo E Guillen
- Department of Vaccines, Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
| |
Collapse
|
|
3
|
Li S, Li N, Yang S, Deng H, Li Y, Wang Y, Yang J, Lv J, Dong L, Yu G, Hou X, Wang G. The study of immune checkpoint inhibitors in chronic hepatitis B virus infection. Int Immunopharmacol 2022; 109:108842. [DOI: 10.1016/j.intimp.2022.108842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Revised: 04/19/2022] [Accepted: 05/04/2022] [Indexed: 11/09/2022]
|